DISCO Pharmaceuticals

DISCO Pharmaceuticals, operating in Cologne, Germany, and Schlieren, Switzerland, uses disruptive scalable technology to map the surface of cancer cells and develop first-class anti-cancer drugs. With the emergence of new cell surface-targeted therapeutic modalities (including ADCs and bispecific antibodies), accelerating the discovery of meaningful targets is crucial. To this end, DISCO comprehensively identifies druggable targets and protein communities (i.e., different proteins that form nanoscale organizations on cells) across the entire surface of cancer cells, revealing important new information that cannot be provided by genomic or transcriptomic sequencing. By understanding which proteins are truly present on the cell surface and how they associate within protein communities, DISCO can design highly specific binders, thereby enhancing intended efficacy and reducing side effects.